Navigation Links
EntreMed Reports Third Quarter 2008 Financial Results
Date:11/6/2008

ers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell cycle regulation, cell signaling and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, pr
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
2. EntreMed to Present at BioPartnering Europe Conference
3. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
4. EntreMed Reports Second Quarter 2008 Financial Results
5. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
6. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
7. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
8. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
9. EntreMed Receives Nasdaq Deficiency Notice
10. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
11. EntreMed Announces 2008 Corporate and Clinical Program Priorities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014 Barnhardt Manufacturing Company ... its Organic Cotton . The USDA Certified Biobased ... biobased ingredients meets or exceeds levels set by USDA. ... whole or in significant part of agricultural, forestry, or ... Organic cotton to be immediately identified as a USDA ...
(Date:9/19/2014)... , September 19, 2014 , ... European Society for Paediatric Endocrinology (ESPE) Meeting  ... and medical research in the field of growth  , ... Darmstadt, Germany , today announced the ... for 2014. The awards were announced during a Satellite ...
(Date:9/18/2014)... TX (PRWEB) September 18, 2014 ... integrated urological and interventional radiology products and services, ... known as cryotherapy and cryoablation) versus external beam ... Section of the American Urological Association (MAAUA) Annual ... , "Comparing Relative Effectiveness of Cryosurgery and External ...
(Date:9/18/2014)... A novel robotic system that can operate inside ... tested as part of a biomedical research partnership program ... aim of determining if the robot, in conjunction with ... more accurate, less costly, and less discomforting for the ... deliver prostate cancer therapies with greater precision. , Developed ...
Breaking Biology Technology:Barnhardt Manufacturing Company Earns USDA Certified Biobased Product Certification and Label for Organic Cotton 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 5Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 6
... Telik, Inc.,(Nasdaq: TELK ) announced that the ... partial hold on TELCYTA(R) (canfosfamide HCl, TLK286),clinical trials. ... data by,the agency and permits the resumption of ... Alto, CA is a biopharmaceutical company focused on,discovering, ...
... Show Lower Dose Associated with Fewer Adverse Events in Healthy ... ... ,GlaxoSmithKline,s (NYSE: GSK ) HIV protease inhibitor LEXIVA(R),(fosamprenavir calcium) may now ... level of protease inhibitors in the,bloodstream. The U.S. Food and Drug ...
... Standards, HOFFMAN ESTATES, Ill., Oct. 12 ... which failed quality testing,ConsumerLab.com anonymously purchased, tested and ... CNCA, a leading national distributor,of premium dietary supplements ... health and wellness., "ConsumerLab.com testing showed that ...
Cached Biology Technology:FDA Removes Partial Hold on TELCYTA Clinical Development 2FDA Approves Administration of LEXIVA(R) with Lower Dose of 'Boosting' Medication Ritonavir 2FDA Approves Administration of LEXIVA(R) with Lower Dose of 'Boosting' Medication Ritonavir 3FDA Approves Administration of LEXIVA(R) with Lower Dose of 'Boosting' Medication Ritonavir 4CNCA Exceeds Standards in Nutritional Supplement Quality, Protects Public 2CNCA Exceeds Standards in Nutritional Supplement Quality, Protects Public 3
(Date:9/18/2014)... have built the first smartphone app that automatically ... trends. In other words, your smartphone knows your ... -- and how that affects you. , The ... and loneliness to their academic performance, also may ... example, to monitor mental health, trigger intervention and ...
(Date:9/18/2014)... 18, 2014Many Americans across racial and ethnic groups ... impact on their day-to-day life, more so than ... and speech (57% of African-Americans, 49% of non-Hispanic ... When asked which disease or ailment is the ... first among African-Americans followed by AIDS/HIV. Hispanics ...
(Date:9/18/2014)... several disciplines will be celebrated tonight at the third ... improving the health of premature infants and in paving ... researchers, whose work was supported by the National Science ... Atomic Energy Commission, will be honored at a ceremony ... bipartisan group of Members of Congress will be on ...
Breaking Biology News(10 mins):New Dartmouth smartphone app reveals users' mental health, performance, behavior 2New Dartmouth smartphone app reveals users' mental health, performance, behavior 3New Dartmouth smartphone app reveals users' mental health, performance, behavior 4Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 33rd annual Golden Goose award ceremony honors 8 researchers; Unusual work had big results 2
... who initially survive a heart attack, a significant cause of ... literally, bursting of the heart wall. A new ... as the key player in the biochemical cascade that leads ... Advance Online Publication (AOP) of the journal Nature Medicine, ...
... new study, led by PRBO Conservation Science (PRBO), projects a ... sea-level rise scenarios that are increasingly likely. PRBO and ... San Francisco Bay,s tidal marsh could be lost in the ... sea-level rise, low sediment availability and no significant restoration]. ...
... are started in-ground, then sold as bare-root ,liners, to ... To minimize wind damage and to facilitate transport from ... buried deeper than necessary. This deep planting of liners ... important foundations of root systems responsible for trees, health ...
Cached Biology News:Study explains how heart attack can lead to heart rupture 2Study explains how heart attack can lead to heart rupture 3Bleak future for Bay area tidal marshes? 2Bleak future for Bay area tidal marshes? 3Bleak future for Bay area tidal marshes? 4Planting depth's effect on container-grown trees 2